Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Terrosa

Sanofi reception

Sanofi indicted in France over epilepsy drug birth defects

Faces allegations over a failure to warn women about risks associated with drug

- PMLiVE

HIV vaccine based on Sanofi/GSK components fails trial

Data suggested vaccine was no more effective than placebo

- PMLiVE

Merck gets Alzheimer’s label claim for insomnia drug Belsomra

Alzheimer's patients typically experience poor sleep

- PMLiVE

FDA accepts priority review for Merck’s antibiotic combo Recarbrio

If approved would provide new option for hard-to-treat infections

- PMLiVE

Lilly launches migraine med Reyvow at $640 per eight-pill pack

Enters increasingly competitive market

- PMLiVE

Givlaari, Rybelsus lead crowded CHMP recommendations

EU regulator delivered 15 positive opinions and no rejections

Bristol Myers Squibb logo

Another blow for BMS in first-line NSCLC as it pulls EU filing

Opdivo/Yervoy combination is still under review with the FDA

- PMLiVE

Lilly posts higher-than-expected profit as new drugs lift outlook

Sales boosted by growth of Trulicity and Taltz

- PMLiVE

It’s Brexit day – now comes the really hard stuff

Months of trade negotiations between UK and EU lie ahead

- PMLiVE

Will biosimilars ever catch on in the US?

Why biosimilars are viewed in the US as ‘me too’ drugs rather than as just-as-good alternatives to branded products

- PMLiVE

Roche posts minor sales miss in Q4 as biosimilar pressure grows

Swiss pharma still managed an 8% increase in pharma sales

Sanofi reception

Sanofi’s rare disease drug olipudase alfa scores in late-stage study

Met crucial endpoints across two clinical studies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links